• 1
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001; 51: 1536.
  • 2
    Fowler JE, Bigler SA, White PC, Duncan WL. Hormone therapy for locally advanced prostate cancer. J Urol. 2002; 168: 546549.
  • 3
    Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and gosarelin. N Engl J Med. 1997; 337: 295300.
  • 4
    Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer. 1998; 83: 15611566.
  • 5
    Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant bone loss. Urology. 1998; 54: 607611.
  • 6
    Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavenier C. Bone mineral density in men treated with gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999; 161: 12191222.
  • 7
    Higano CS, Stephens C, Nelson PS, et al. Prospective serial measurements of bone mineral density in prostate cancer patients without bone metastases who are treated with intermittent androgen suppression [abstract]. Proc Am Soc Clin Oncol. 1999; 18: 314a.
  • 8
    Suzuki Y, Aikawa K, Oishi Y, et al. [ A clinical study of decreased bone density in patients treated with long term luteinising hormone-releasing hormone analogue (LHRH-a)—the risk of iatrogenic osteoporosis due to treatment of carcinoma of the prostate]. Nippon Hinyokika Gakkai Zasshi. 1998; 12: 961966.
  • 9
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000; 163: 181186.
  • 10
    Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001; 86: 27872791.
  • 11
    Diamond T, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. A double blind, randomized, placebo-controlled crossover study. Cancer. 2001; 92: 14441450.
  • 12
    Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med. 2001; 345: 948955.
  • 13
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003; 169: 20082012.
  • 14
    Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002; 167: 23612367.
  • 15
    Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder J. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002; 87: 36563661.
  • 16
    Coates PS, Wagner J, Ribich J, Trump DL, Nelson JB, Greenspan SL. Acute androgen deprivation causes early rapid bone loss: a longitudinal study [abstract]. J Bone Miner Res. 2002; 17: 155.
  • 17
    Preston DM, Torrens JI, Harding P, Howard RS, Duncan WE, McLeod DG. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis. 2002; 5: 304310.
  • 18
    Bruder JM, Welch MD. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen deprivation [abstract]. J Bone Miner Res. 2002; 17: 411.
  • 19
    Yaturu S, DePrisco C, DjoDjo S. Effect of bisphosphonates in osteoporosis secondary to LHRH analogs for prostate cancer [abstract]. J Bone Miner Res. 2002; 17: 474.
  • 20
    Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol. 1997; 157: 439444.
  • 21
    Townsend MF, Sanders WH, Northway RO, Graham SD. Bone fractures associated with luteinizing hormone-releasing agonists used in the treatment of prostate cancer. Cancer. 1997; 79: 545550.
  • 22
    Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinising hormone-releasing hormone agonists for prostate cancer. BJU Int. 2000; 86: 449452.
  • 23
    Oefelein M, Ricchuitti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001; 166: 17241728.
  • 24
    Modi S, Wood L, Siminoski K, et al. A comparison of the prevalence of osteoporosis and vertebral fractures in men with prostate cancer on various androgen deprivation therapies: preliminary report [abstract]. Proc Am Soc Clin Oncol. 2001; 20 Suppl B: 167.
  • 25
    Melton LJ, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zinke H. Fracture risk following bilateral orchiectomy. J Urol. 2003; 169: 17471750.
  • 26
    Elliott ME, Wilcox AJ, Carnes ML, et al. Androgen deprivation in veterans with prostate cancer: implications for skeletal health [abstract]. J Bone Miner Res. 2002; 17: 366.
  • 27
    Melton LJ, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Miner Res. 1998; 13: 19151923.
  • 28
    Binkley NC, Schmeer P, Wasnich RD, Lenchik L. What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians? J Clin Densitom. 2002; 5 Suppl: S19S27.
  • 29
    WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organization, 1994.
  • 30
    Zmuda JM, Cauley JA, Glynn NY, Finkelstein JS. Posterior-anterior and lateral dual-energy X-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men. J Bone Miner Res. 2000; 15: 14171424.
  • 31
    Faulkner KG. Bone densitometry: choosing the proper skeletal site to measure. J Clin Densitom. 1998; 1: 279285.
  • 32
    Weigert JM, Cann CE. 3D QCT: a useful tool in following therapy. In: International Society of Clinical Densitometry. Proceedings of the 4th Annual Scientific Meeting of the International Society of Clinical Densitometry. West Hartford: ISCD, 1988: 14.
  • 33
    Kaufman JM, Johnell O, Abadie E, et al. Background for the studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis. 2000; 59: 765772.
  • 34
    Lenchik L, Kiebzak GM, Blunt BA. What is the role of serial bone mineral density measurements in patient management? J Clin Densitom. 2002; 5 Suppl: S29S38.
  • 35
    Delaet C, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res. 1998; 13: 15871593.
  • 36
    Jones G, Nguyen T, Sambrook P, Kelly P, Eisman JA. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo Osteoporosis Epidemiology Study. BMJ. 1994; 309: 691695.
  • 37
    Stepan JJ, Lachman MA, Svereina J, Pacovsky V, Baylink D. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodelling. J Clin Endocrinol Metab. 1989; 69: 523527.
  • 38
    Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001; 57: 127132.
  • 39
    Clarke BL, Ebeling PR, Jones JD, et al. Changes in qualitative bone histomorphometry in aging healthy men. J Clin Endocrinol Metab. 1996; 81: 22642270.
  • 40
    Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998; 83: 22662274.
  • 41
    Jackson JA, Kleerekoper M. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab. 1987; 65: 5358.
  • 42
    Orwoll ES. Men, bone and estrogen: unresolved issues. Osteoporos Int. 2003; 14: 9398.
  • 43
    Garnero P, Buch N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000; 82: 858864.
  • 44
    Noguchi M, Noda S. Pyridinoline cross-linked carboxyterminal telopeptide of Type 1 collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol. 2001; 166: 11061110.
  • 45
    Dawson NA. Bisphosphonates: their evolving role in the management of prostate cancer-related bone disease. Curr Opin Urol. 2002; 12: 413428.
  • 46
    Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 14581468.
  • 47
    Dennison E, Cooper C. The epidemiology of osteoporosis. Br J Clin Pract. 1996; 50: 3336.
  • 48
    Sambrook PN, Phillips SR, Seeman E, Ebeling PR. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust. 2002; 176 Suppl: S1S16.
  • 49
    Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med. 1997; 103 Suppl 2A: 12S19S.
  • 50
    Diamond T, Thornley S, Sekel R, Smerdely P. Hip fracture in elderly men: prognostic factors and outcomes. Med J Aust. 1997; 167: 412415.
  • 51
    Baillie SP, Davison CE, Johnson FJ, Francis RM. Pathogenesis of vertebral crush fractures in men. Age Ageing. 1992; 21: 139141.
  • 52
    Jackson JA, Spiekerman AM. Testosterone deficiency is common in men with hip fracture after simple falls. Clin Res. 1989; 37: 131136.
  • 53
    Genant HK, Wu CY, Van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8: 11371148.
  • 54
    Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343: 604610.
  • 55
    Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab. 2001; 86: 52525255.
  • 56
    Orwoll E, Scheele WH, Clancy AD, et al. Recombinant human parathyroid hormone (1-34) therapy reduces the incidence of moderate/severe vertebral fractures in men with low bone density [abstract]. J Bone Miner Res. 2001; 16: 162.
  • 57
    Diamond T, Sambrook P, Williamson M, et al. Guidelines for the treatment of osteoporosis in men for general practitioners. Aust Fam Physician. 2001; 30: 787791.
  • 58
    Delmas PD. Bisphosphonates in the treatment of bone disease. N Engl J Med. 1996; 24: 18361837.
  • 59
    Russell RG, Croucher PI, Rogers MJ. Biphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int. 1999; 9 Suppl 2: S66S80.
  • 60
    Marcus R, Wong M, Heath H, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev. 2002; 23: 1637.
  • 61
    Papapoulos SE, Hamdy NA, Van der Pluijm G. Bisphosphonates in the management of prostate carcinoma metastatic to bone. Cancer. 2000; 88: 30473053.
  • 62
    Smith JA Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol. 1989; 141: 8587.
  • 63
    Kylmala T, Taube T, Tammela TL, Risteli L, Risteli J, Elomaa I. Concomitant i.v. and oral clodronate in the relief of bone pain—a double-blind, placebo-controlled study in patients with prostate cancer. Br J Cancer. 1997; 76: 939942.